Loading clinical trials...
Loading clinical trials...
Blood Biomarkers to Improve Management of Mild Traumatic BRAIN Injury in the Elderly
Mild traumatic brain injury (mTBI) is one of the most frequent emergencies in the elderly population. Despite most mTBI are managed with cranial computed tomography (CT), only 10% of CTs show lesions, determining CT overuse. The use of serum glial fibrillary acidic protein (GFAP) and Ubiquitin C-terminal Hydrolase-L1 (UCH-L1) have shown potential for ruling out the need for cranial CT. However evidence on biomarker use in mild TBI were not based on studies that included aged participants and patients with comorbidities for which biomarker levels could vary. This is why there is a need for a prospective study that assesses the predictive performance of these two biomarkers in the elderly population, both in elderly patients suffering mild TBI and in a reference population, including patients and participants with and without comorbidities.
Age
65 - No limit years
Sex
ALL
Healthy Volunteers
Yes
CHU Clermont-Ferrand
Clermont-Ferrand, France
CHU Grenoble-Alpes
Grenoble, France
Hôpital Edouard HERRIOT
Lyon, France
Hôpital Lyon Sud HCL
Lyon, France
Klinikum rechts der Isar
Munich, Germany
Hospital Universitario 12 de Octubre
Madrid, Madrid, Spain
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Start Date
March 1, 2022
Primary Completion Date
December 31, 2024
Completion Date
March 30, 2025
Last Updated
December 29, 2025
2,297
ACTUAL participants
GFAP and UCH-L1
DIAGNOSTIC_TEST
Lead Sponsor
Hospital Universitario 12 de Octubre
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07202494